EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Role of B cells in immune‐related adverse events following checkpoint blockade

Kavita M Dhodapkar iD, Alyssa Duffy, Madhav V Dhodapkar iD

Immunological Reviews · 2023-09 · 318 (1) · 89-95

DOI: 10.1111/imr.13238 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 08.07.2023. Verfasst von Kavita M Dhodapkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatric Hematology/Oncology, Emory University, Atlanta, Ge…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blockade of immune checkpoints has transformed the therapy of several cancers. However, immune‐related adverse events (irAEs) have emerged as a major challenge limiting the clinical application of this approach. B cells are recognized as major players in the pathogenesis of human autoimmunity and have been successfully targeted to treat these disorders. While T cells have been extensively studied as therapeutic targets of immune checkpoint blockade (ICB), these checkpoints also impact B cell tolerance. Blockade of immune checkpoints in the clinic is associated with distinct changes in the B cell compartment that correlate with the development of irAEs. In this review, we focus on the possible role of humoral immunity, specifically human B cell subsets and autoantibodies in the pathogenesis of ICB‐induced irAEs. There remains an unmet need to better understand the T:B cell cross talk underlying the activation of pathogenic B cells and the development of ICB‐induced irAEs. Such studies may identify new targets or approaches to prevent or treat irAEs and improve the application of ICB therapy in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansB-LymphocytesAutoimmunityImmune Checkpoint InhibitorsAutoantibodiesImmunotherapy

Stichwörter der Autor:innen

B cellsadverse eventsautoimmunitycancerimmune checkpoint blockademechanism

Substanzen

Immune Checkpoint InhibitorsAutoantibodies

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia, USA.
  • Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Kavita M Dhodapkar, Madhav V Dhodapkar

Förderung

  • NIAMS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Dhodapkar, K. M., Duffy, A., & Dhodapkar, M. V. (2023). Role of B cells in immune‐related adverse events following checkpoint blockade. Immunological Reviews, 318(1), 89-95. https://doi.org/10.1111/imr.13238

Vancouver

Dhodapkar KM, Duffy A, Dhodapkar MV. Role of B cells in immune‐related adverse events following checkpoint blockade. Immunological Reviews. 2023;318(1):89-95. doi:10.1111/imr.13238

BibTeX
@article{Dhodapkar2023,
  author = {Dhodapkar, Kavita M and Duffy, Alyssa and Dhodapkar, Madhav V},
  title = {Role of B cells in immune‐related adverse events following checkpoint blockade},
  journal = {Immunological Reviews},
  year = {2023},
  volume = {318},
  number = {1},
  pages = {89--95},
  doi = {10.1111/imr.13238}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche